Skip to main content
AAPL-0.36%MSFT+0.84%NVDA+3.92%GOOGL-1.24%AMZN+0.73%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.61%TSLA+0.92%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+4.23%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.63%NZDJPY-0.62%AUDUSD-0.53%NZDUSD-0.49%GBPAUD+0.44%EURJPY-0.43%GBPNZD+0.43%GBPTRY+0.41%CHFJPY-0.40%CADJPY-0.35%GBPHKD+0.32%USDCHF+0.32%EURUSD-0.31%AUDCAD-0.29%GBPMXN-0.28%NZDCAD-0.27%GBPCHF+0.25%AUDCHF-0.24%EURGBP-0.24%USDCAD+0.24%EURAUD+0.22%NZDCHF-0.20%GBPJPY-0.18%EURNZD+0.18%USDTHB-0.18%GBPCAD+0.16%USDILS+0.16%USDTRY+0.16%USDJPY-0.13%USDCNH-0.11%USDDKK+0.10%NZDMXN+0.09%AUDNOK+0.09%EURCNH-0.09%CHFSGD-0.09%NZDSGD+0.08%EURSGD-0.08%CADCHF+0.07%EURCAD-0.07%SGDJPY+0.07%GBPUSD-0.06%AUDSGD+0.04%USDCOP-0.04%AUDNZD-0.04%USDMXN+0.03%GBPSGD-0.02%USDSGD+0.02%EURCHF+0.01%USDHKD+0.01%USDZAR-0.01%EURDKK0.00%CHFNOK0.00%EURNOK0.00%EURSEK0.00%EURCZK0.00%NOKJPY0.00%USDPLN0.00%GBPZAR0.00%PLNJPY0.00%USDNOK0.00%USDSEK0.00%EURHKD0.00%EURPLN0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%XNGUSD+0.66%GAUUSD-0.25%XAUUSD-0.25%GAGUSD-0.19%XAGUSD-0.19%XPTUSD-0.16%USOIL-0.06%HG1+0.04%COFFEE0.00%COCOA0.00%W10.00%S10.00%BTCUSD-0.06%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.99%ZECUSDT+6.64%XMRUSDT+3.18%DOGEUSD+59.04%LINKUSD+1.49%XLMUSD+2.73%BCHUSDT+1.59%LTCUSD+50.36%UNIUSD+2.32%TONUSD+63.46%SUIUSD+2.22%HBARUSDT+1.20%TAOUSDT+3.06%AAVEUSD+3.40%ONDOUSDT+1.11%ICPUSDT-8.38%DOTUSDT+1.32%WLDUSDT+2.24%ARBUSDT+0.83%INJUSDT+7.93%ATOMUSDT-0.32%STXUSDT+5.89%PYTHUSDT+2.26%TIAUSDT+0.91%FETUSDT+0.68%SEIUSDT+3.60%JUPUSDT+8.60%GRTUSDT+4.68%OPUSDT-2.36%IOTAUSDT+3.18%POLUSDT+4.29%WIFUSDT+1.17%AXSUSDT+1.71%EOSUSDT+2.67%FARTCOINUSDT-1.03%IMXUSDT+3.03%GALAUSDT-1.23%DYDXUSDT+2.54%ORDIUSDT+0.39%NOTUSDT+1.77%RONINUSDT+2.00%AAPL-0.36%MSFT+0.84%NVDA+3.92%GOOGL-1.24%AMZN+0.73%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.61%TSLA+0.92%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+4.23%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.63%NZDJPY-0.62%AUDUSD-0.53%NZDUSD-0.49%GBPAUD+0.44%EURJPY-0.43%GBPNZD+0.43%GBPTRY+0.41%CHFJPY-0.40%CADJPY-0.35%GBPHKD+0.32%USDCHF+0.32%EURUSD-0.31%AUDCAD-0.29%GBPMXN-0.28%NZDCAD-0.27%GBPCHF+0.25%AUDCHF-0.24%EURGBP-0.24%USDCAD+0.24%EURAUD+0.22%NZDCHF-0.20%GBPJPY-0.18%EURNZD+0.18%USDTHB-0.18%GBPCAD+0.16%USDILS+0.16%USDTRY+0.16%USDJPY-0.13%USDCNH-0.11%USDDKK+0.10%NZDMXN+0.09%AUDNOK+0.09%EURCNH-0.09%CHFSGD-0.09%NZDSGD+0.08%EURSGD-0.08%CADCHF+0.07%EURCAD-0.07%SGDJPY+0.07%GBPUSD-0.06%AUDSGD+0.04%USDCOP-0.04%AUDNZD-0.04%USDMXN+0.03%GBPSGD-0.02%USDSGD+0.02%EURCHF+0.01%USDHKD+0.01%USDZAR-0.01%EURDKK0.00%CHFNOK0.00%EURNOK0.00%EURSEK0.00%EURCZK0.00%NOKJPY0.00%USDPLN0.00%GBPZAR0.00%PLNJPY0.00%USDNOK0.00%USDSEK0.00%EURHKD0.00%EURPLN0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%XNGUSD+0.66%GAUUSD-0.25%XAUUSD-0.25%GAGUSD-0.19%XAGUSD-0.19%XPTUSD-0.16%USOIL-0.06%HG1+0.04%COFFEE0.00%COCOA0.00%W10.00%S10.00%BTCUSD-0.06%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.99%ZECUSDT+6.64%XMRUSDT+3.18%DOGEUSD+59.04%LINKUSD+1.49%XLMUSD+2.73%BCHUSDT+1.59%LTCUSD+50.36%UNIUSD+2.32%TONUSD+63.46%SUIUSD+2.22%HBARUSDT+1.20%TAOUSDT+3.06%AAVEUSD+3.40%ONDOUSDT+1.11%ICPUSDT-8.38%DOTUSDT+1.32%WLDUSDT+2.24%ARBUSDT+0.83%INJUSDT+7.93%ATOMUSDT-0.32%STXUSDT+5.89%PYTHUSDT+2.26%TIAUSDT+0.91%FETUSDT+0.68%SEIUSDT+3.60%JUPUSDT+8.60%GRTUSDT+4.68%OPUSDT-2.36%IOTAUSDT+3.18%POLUSDT+4.29%WIFUSDT+1.17%AXSUSDT+1.71%EOSUSDT+2.67%FARTCOINUSDT-1.03%IMXUSDT+3.03%GALAUSDT-1.23%DYDXUSDT+2.54%ORDIUSDT+0.39%NOTUSDT+1.77%RONINUSDT+2.00%
EL

Eli Lilly and Company (LLY)

NYSE • Healthcare

$1415.55
-$16.12 (-1.1%)
Market closed

November 17, 2026 at 21:00 UTC

Open$1416
Day Range$1401.66 - $1432.28
Avg. Volume (3M)3M
Market Cap$1.3T
P/E Ratio45.8
52 Week Range
$850.51$1475.25
Next EarningsIn 77 daysFeb 3, 2027

Interactive Chart

00:18:56 UTC

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$24.3B100%
Gross Profitminus cost of goods$20.4B84%
Operating Incomeminus R&D and overhead$8.6B35%
Net Incomeminus taxes and the rest$6.4B26%

In plain terms: out of every $100 in revenue, Eli Lilly and Company keeps $26 as net profit.

Fundamentals & Financials

Revenue (TTM)
$86.4B
Net Income (TTM)
$27.5B
EPS (TTM)
$30.89
ROA (TTM)
18.63%
Current Ratio
1.39
Dividend Yield
0.15%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+22.7%Q2 2026$8.55
+30.9%Q3 2026$8.38
+31.0%Q4 2026$7.48
Next

Feb 3

in 77 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +31.0%

Eli Lilly beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported October 29, 2026, with adjusted EPS of $7.48 topping the $5.68 estimate (+31.7%) and revenue of $24.397 billion topping the $22.583 billion estimate (+8%). Revenue rose about 39% year over year to roughly $24.4 billion (up from about $17.6 billion a year ago), with sales concentrated in the U.S., where revenue climbed about 34% to roughly $15.1 billion, while Rest of world grew nearly 90% to about $3.2 billion and China increased about 69% to roughly $947 million. Profitability remained elevated, with operating income of about $8.9 billion translating to an operating margin of roughly 37%. Net income rose about 16% year over year to roughly $6.5 billion (up from about $5.6 billion a year ago). Lilly generated about $11.4 billion of operating cash flow during the quarter and returned cash through roughly $377 million of share repurchases alongside about $1.5 billion in dividends. For the next period, consensus calls for EPS of $10.57 on revenue of $24.054 billion.

View full earnings history

About Eli Lilly and Company

Eli Lilly and Company researches, develops, and commercializes human medicines, operating as a large pharmaceutical company listed on the NYSE as LLY. Its portfolio spans diabetes, oncology, immunology, neuroscience, and other specialty therapies, and it recorded $65.2 billion of revenue in FY2025.

Name
Eli Lilly and Company
CEO
David A. Ricks
Industry
Healthcare
Year Founded
1876
Employees
50,000

Today's Snapshot

AI-generated

LLY closed 1.1% lower at 1415.43, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level. Eli Lilly won FDA approval for Retevmo, its cancer treatment.

Trading Volume

Below 10d avg (3.1M)

1.9M

vs S&P 500 Today

Moderate Outperformance

+0.22%

Updated: November 17, 2026 at 21:07 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
LLY displays a robust bullish profile with the price well above short-, medium- and long-term moving averages and a strong ADX that signals a solid uptrend. Momentum readings are positive and MACD is elevated, supporting the bullish stance, while RSI sits in a constructive range rather than being overbought. Volatility is moderate relative to the stock’s level, and on-balance volume is not confirming, which tempers the strength somewhat. Technical takeaway: Strong Buy, driven by broad moving-average strength and a strong directional trend.
All signals
  • EMA (5 indicators)$1144.19 - $1410.87
    Buy
  • RSI (14)63.02
    Neutral
  • Stochastic %K (14, 3, 3)76.79
    Neutral
  • MACD Level (12, 26)52.81
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.